RVL Pharmaceuticals plc (RVLP) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
400 Crossing Boulevard
Bridgewater, NJ 08807
United States of America (the)
Phone
908 809 1300
Website
Sector
Healthcare
Industry
Biotechnology
Employees
125
First IPO Date
October 19, 2018
| Name | Title | Pay | Year Born |
| Brian A. Markison | Chairman, President, Chief Executive Officer & Principal Financial Officer | 525,000 | 1959 |
| Christopher A. Klein | General Counsel & Secretary | 367,200 | 1965 |
| Jarret Miller | Executive Vice President of Human Resources | 0 | N/A |
RVL Pharmaceuticals plc operates as a specialized pharmaceutical firm, concentrating on the creation and commercialization of medicinal products. These offerings target patient populations with unmet needs within the fields of ocular health and medical aesthetics across the United States, Argentina, and Hungary. Among its key commercialized products is Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution specifically developed for adults experiencing acquired blepharoptosis, or drooping eyelids. The company, whose corporate headquarters are located in Bridgewater, New Jersey, underwent a name change in January 2022, transitioning from its former identity as Osmotica Pharmaceuticals plc.